Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.
about
Preclinical Evaluation of Microneedle Technology for Intradermal Delivery of Influenza VaccinesCAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferretsHeterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children<3 years of age.Model answers or trivial pursuits? The role of mathematical models in influenza pandemic preparedness planningLong-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults.Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial.Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic.Quality and kinetics of the antibody response in mice after three different low-dose influenza virus vaccination strategies.AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial.Pandemic H5N1 influenza vaccine development: an update.Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial.Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.Induction of Local Secretory IgA and Multifunctional CD4⁺ T-helper Cells Following Intranasal Immunization with a H5N1 Whole Inactivated Influenza Virus Vaccine in BALB/c Mice.Current status and progress of prepandemic and pandemic influenza vaccine development.Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challengeVaccines for an influenza pandemic: scientific and political challenges.A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza virusesCharacterization of a whole, inactivated influenza (H5N1) vaccine.A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus.A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults.Evaluation of multivalent H2 influenza pandemic vaccines in mice.Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized studyPandemic influenza vaccines - the challenges.Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older.Adjuvant effect of docetaxel on the immune responses to influenza A H1N1 vaccine in mice.Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunitySafety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults.Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adultsLow immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: results of a prospective pilot studyEvaluation of MDCK cell-derived influenza H7N9 vaccine candidates in ferretsInternational Laboratory Comparison of Influenza Microneutralization Assays for A(H1N1)pdm09, A(H3N2), and A(H5N1) Influenza Viruses by CONSISEEfficacy of a heterologous vaccine and adjuvant in ferrets challenged with influenza virus H5N1.Immunogenetics of seasonal influenza vaccine responseInfluenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patientsWhole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs.Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults.Rapid-response vaccines--does DNA offer a solution?Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination.Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice.
P2860
Q27478355-E541943C-DB6E-418E-B139-D461D2584006Q28741710-0EF874B2-1591-4434-BC51-ED90D3BDA220Q30209583-3B55DD10-1E55-4395-934B-EC9394DED225Q30230076-A016466B-E8F8-4ED6-9EE4-522669ADE259Q30360190-728259C4-112C-435A-9BDF-842C0F6DC7F3Q30360483-946CF737-3917-43C4-8A47-ADFA8B037B78Q30360869-363A0CB5-EB59-4B7A-9CA1-BFBA459E5F5EQ30362618-4F8B8C27-8200-4CA5-8797-0310C4E2F169Q30367603-9CF5B4C1-5D8A-4CC8-B95F-DBD9E362A023Q30368132-68C88338-58FD-4CCE-951A-05C573892CC1Q30372167-D99F83C3-756C-44D7-AA1D-C08AF3D5F642Q30372195-6C2CB1EA-6251-4E55-9C43-4CE742FFA3F1Q30372360-BB9AA6F6-5138-4BAB-9F8E-F15DC9AB7BF9Q30375975-CCD1346B-402B-4C12-95E2-E01C11D00BF3Q30376482-7DB7DA9A-2218-4465-AF41-587309E45C17Q30376971-E6B40B67-7D36-4748-9F93-601D45ABBF0DQ30377217-EE3EBF38-AFD0-4DE5-9B8C-A5E7ADBEA728Q30377220-F78E257C-AC70-4B15-8F7B-451BE8939F66Q30392828-A6D16589-6453-42FF-9DDE-30FD9EBA8897Q30396693-AE3A2CBA-B211-41A2-B016-4042ADC14C35Q30398507-1472D019-C1C4-42EE-9F53-BDE6674EA8D8Q30403078-52518B7B-3E75-4CD6-8D28-4AF75ABB37CFQ30408091-FB25B35C-47F2-4FFE-8186-3D86D7D90981Q34067461-67CD25ED-9A11-4D29-A4C9-10D3613546D3Q34329446-7F4A753C-F224-480A-9399-54ABC7E2B162Q34416393-14939AF2-DD0D-4A89-95C4-C9919C40A8D0Q34498228-BD52F1BA-3F57-4433-976A-C9B2069445EAQ34729188-C2249A85-ED4E-442D-8A1F-D7B8EDC833B2Q35034566-F3ECF448-CECE-4784-B479-04BCE6F5D0ABQ35208516-7E6BCB53-EE46-4735-9444-D0F02F8ACABFQ35901999-37C8BEBF-FAB4-49F7-A42A-2784591C20F4Q36140851-C2766C02-6F7D-4AAB-BF40-37B7675691D8Q37030332-AEFB4C9A-B419-411D-8756-939BCA28CA99Q37071008-80FAC24C-AE5D-4368-A15F-35351F45DD64Q37087655-88E35C8A-3926-4580-9408-6CE59FF9947EQ37316012-B22BF298-BEBA-41C2-83DE-721F5388D7E3Q40390503-5F1D72EF-DC82-4B02-B89B-32801B1BE36FQ42221819-51E64E24-DF3D-40AC-A0F6-7250A83B607BQ45428083-6B54B832-9841-4704-BEB2-1253C92C8C53
P2860
Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Immunogenicity of a monovalent ...... irus vaccine for pandemic use.
@ast
Immunogenicity of a monovalent ...... irus vaccine for pandemic use.
@en
type
label
Immunogenicity of a monovalent ...... irus vaccine for pandemic use.
@ast
Immunogenicity of a monovalent ...... irus vaccine for pandemic use.
@en
prefLabel
Immunogenicity of a monovalent ...... irus vaccine for pandemic use.
@ast
Immunogenicity of a monovalent ...... irus vaccine for pandemic use.
@en
P2093
P1433
P1476
Immunogenicity of a monovalent ...... irus vaccine for pandemic use.
@en
P2093
P304
P356
10.1016/J.VIRUSRES.2004.02.029
P577
2004-07-01T00:00:00Z